Skip to content

Factors Associated with Falling in Parkinson's Disease

Factors Associated with Falling in Parkinson's Disease: a Multidisciplinary Prospective Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04440033
Enrollment
10
Registered
2020-06-19
Start date
2020-10-12
Completion date
2023-12-01
Last updated
2024-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson Disease

Keywords

Parkinson's Disease, Accidental Falls, Risk factor, Gait, Speech, Audiology

Brief summary

The objective of this study will be to identify multidisciplinary fall risk factors in persons with stage 3 idiopathic Parkinson's Disease compared to age and sex-matched healthy adults. Both the relative contribution of each independent factor, as well as the interaction between these factors, will be examined. The study will include multidisciplinary assessments, including locomotor, speech, auditory, vestibular and opthalmologic assessments.

Interventions

OTHERBaseline assessment of demographic, anthropometric and clinical characteristics

* Age * Sex * Height * Body weight * Handedness * Medication use * Blood pressure * Global cognition (Montreal Cognitive Assessment) * Fear of falling (Shortened Iconographical Falls Efficacy Scale) * History of falls (number of falls in the past month) * Time since diagnosis and symptom onset * Disease severity (UPDRS part III, Hoehn and Yahr) * Non-motor symptoms (UPDRS part I) * Motor symptoms (UPDRS part III) * Motor complications (UPDRS part IV) * Disease-dominant side (UPDRS part III) * Freezing of gait (New Freezing of Gait Questionnaire)

OTHERLocomotor assessments

First, 9 anthropometric measurements will be taken, 39 reflective markers will be placed, and a 6-min practice walking session will be conducted to familiarize participants with self-paced treadmill walking (SPTW). Thereafter, participants will partake in 7 experimental conditions in a (semi-)randomized order: * 3 min standing * 3 min standing while answering semi-standardized questions * 3 min SPTW * 3 min SPTW while answering semi-standardized questions (SPTW-Q) * 3 min SPTW while verbally describing a VR environment (SPTW-VR1) * 6 min SPTW in a VR environment containing freezing of gait provoking elements (SPTW-VR2)

* Acoustic analysis (including voice reports and formant analysis), video recording and motor speech profile (including analysis of diadochokinesis, voice, standard syllabic rate, intonation and second formant (F2)). * Spontaneous speech production will be assessed by answering semi-standardized questions based on the Aachen Aphasia Test and by describing a VR environment projected on a 180-degree cylindrical screen * The Speech Handicap Index (a 15-item self-reported questionnaire)

OTHERAudiology assessments

* Otoscopy * Tympanometry * Pure tone audiometry * Otoacoustic emissions * Video Head Impuls Test * Cervical Vestibular Evoked Myogenic Potentials * Ocular Vestibular Evoked Myogenic Potentials * Oculomotor function testing * Positional testing * Static visual acuity test * Dynamic visual acuity test * Dizziness Handicap Inventory (a 25-item self-assessment inventory)

Sponsors

University Ghent
CollaboratorOTHER
University Hospital, Ghent
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
NONE

Intervention model description

Case-control

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

Parkinson's Disease group Inclusion criteria: * Persons with idiopathic PD diagnosed by a medical doctor according to the United Kingdom PD Brain Bank Criteria * Aged between 18 and 75 years-old * Stage 3 on the Hoehn and Yahr scale in the on-medication state * On a stable dose of PD medication (at least one week) * Able to stand and walk on a treadmill without support for at least 3 minutes * Able to give consent

Exclusion criteria

* Atypical parkinsonism * Unpredictable symptom fluctuations * Previous surgical management of PD (i.e., deep brain stimulation surgery; pallidotomy) * Duodopa pump therapy * Dementia (Montreal Cognitive Assessment (MoCA) \< 21)\[1\] * Symptomatic orthostatic hypotension (e.g. frequent syncope episodes) * Concurrent neurological disorders (e.g. stroke) * Comorbidities that affect gait or balance (e.g. peripheral neuropathy) * Acute illness * Epilepsy or history of seizures * Depression (MDS-UPDRS item 1.3 ≥ 2) * Body weight over 120 kilograms * Pregnancy * Participation in other ongoing experimental trials Healthy control group Inclusion criteria: * Age and sex-matched healthy adults

Design outcomes

Primary

MeasureTime frameDescription
Fall eventsbaseline to 6 months after baselineNumber of accidental falls documented using a daily fall diary with monthly telephone follow-ups.

Secondary

MeasureTime frameDescription
Walking speedbaseline during 3 min self-paced treadmill walking; baseline during 3 min self-paced treadmill walking while answering semi-standardized questions; baseline during 3 min self-paced treadmill walking while describing a virtual environmentWalking speed (meters/second) measured using the Gait Real-time Interactive Lab (GRAIL) system (Motekforce Link, The Netherlands).
Walking cadencebaseline during 3 min self-paced treadmill walking; baseline during 3 min self-paced treadmill walking while answering semi-standardized questions; baseline during 3 min self-paced treadmill walking while describing a virtual environmentWalking cadence (steps/minute) measured using the Gait Real-time Interactive Lab (GRAIL) system (Motekforce Link, The Netherlands).
Step lengthbaseline during 3 min self-paced treadmill walking; baseline during 3 min self-paced treadmill walking while answering semi-standardized questions; baseline during 3 min self-paced treadmill walking while describing a virtual environmentStep length (meters) measured using the Gait Real-time Interactive Lab (GRAIL) system (Motekforce Link, The Netherlands).
Hip, knee and ankle joint angle during walkingbaseline during 3 min self-paced treadmill walking; baseline during 3 min self-paced treadmill walking while answering semi-standardized questions; baseline during 3 min self-paced treadmill walking while describing a virtual environmentHip, knee and ankle joint angle during walking (°) measured using the Gait Real-time Interactive Lab (GRAIL) system (Motekforce Link, The Netherlands).
Otoacoustic Emissions TestbaselineAn auditory test to measure cochlear outer hair cell function
Hip, knee and ankle joint moment during walkingbaseline during 3 min self-paced treadmill walking; baseline during 3 min self-paced treadmill walking while answering semi-standardized questions; baseline during 3 min self-paced treadmill walking while describing a virtual environmentHip, knee and ankle joint moment during walking (Nm/kg) measured using the Gait Real-time Interactive Lab (GRAIL) system (Motekforce Link, The Netherlands).
Hip, knee and ankle joint power during walkingbaseline during 3 min self-paced treadmill walking; baseline during 3 min self-paced treadmill walking while answering semi-standardized questions; baseline during 3 min self-paced treadmill walking while describing a virtual environmentHip, knee and ankle joint moment during power (W/kg) measured using the Gait Real-time Interactive Lab (GRAIL) system (Motekforce Link, The Netherlands).
Freezing of gaitbaseline during 6 min self-paced treadmill walking in a virtual environmentNumber of freezing of gait events measured using the Gait Real-time Interactive Lab (GRAIL) system (Motekforce Link, The Netherlands).
Spontaneous speech productionbaseline; baseline during 3 min self-paced treadmill walking; baseline during 3 min self-paced treadmill walking while answering semi-standardized questions; baseline during 3 min self-paced treadmill walking while describing a virtual environmentAudio recordings analyzed using PRAAT software to assess spontaneous speech production
Speech Handicap IndexbaselineA 15-item self-reported questionnaire based on the Parole Handicap Index to evaluate the physical, functional and psychosocial impact of dysarthria (0-60). Higher scores indicate a higher level of speech-related problems.
OtoscopybaselineA otoscopic test to examine the external auditory canal and the tympanic membrane
TympanometrybaselineAn auditory test to assess the middle-ear function
Pure tone audiometrybaselineAn auditory test to assess hearing threshold levels
Cervical Vestibular Evoked Myogenic Potential TestingbaselineA vestibular function test to assess the saccular and inferior vestibular nerve function
Ocular Vestibular Evoked Myogenic Potential TestingbaselineA vestibular function test to assess the utricular and superior vestibular nerve function
Ocular Motor TestingbaselineA vestibular function test to evaluate oculomotor function
Dix-Hallpike TestbaselineA diagnostic maneuver to identify benign paroxysmal positional vertigo
Roll TestbaselineA diagnostic maneuver to identify benign paroxysmal positional vertigo
Static visual acuitybaselineStatic visual acuity measured using a Snellen chart (static logMAR)
Dynamic visual acuitybaselineVisual acuity during head movement measured using a Snellen chart relative to static visual acuity (static logMAR - dynamic logMAR)
Dizziness Handicap InventorybaselineA 25-item self-assessment inventory to evaluate self-perceived handicapping effects of dizziness (0-100). Higher scores indicate a greater perceived handicap due to dizziness.
Video Head Impuls TestbaselineA vestibular function test to objectify high frequency function of the horizontal and vertical semicircular canals

Other

MeasureTime frameDescription
AgebaselineYears since birth
SexbaselineMale or female
Montreal Cognitive AssessmentbaselineA screening test to assess global cognition (0-30). Higher scores indicate better performance.
Shortened Iconographical Falls Efficacy ScalebaselineA 10-item scale to assess fear of falling. Each item is scored on a 4-point scale (1 = not at all concerned to 4 = very concerned).
Fall historybaselineNumber of falls in the past month
Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part IbaselineA 13-item rating scale to assess non-motor experiences of daily living (0-52). Higher scores indicate a worse outcome.
Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part IIIbaselineAn 18-item motor examination to assess motor symptoms (0-132). Higher scores indicate a worse outcome.
Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part IVbaselineA 6-item rating scale to assess motor complications. Higher scores indicate a worse outcome.
Hoehn and Yahr scalebaselineA scale to assess disease severity/progression (0-5). Higher scores indicate more severe symptoms.
New Freezing of Gait QuestionnairebaselineA 9-item questionnaire to assess freezing of gait severity (0-28). Higher scores indicate more severe freezing of gait.
Time since diagnosisbaselineThe number of days since the diagnosis of Parkinson's Disease
Blood pressurebaselineThe ratio of systolic over diastolic blood pressure (mm Hg)
MedicationbaselineNumber, type and dose (mg) of medication

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026